These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 546789)

  • 21. Comparison of the reactivities and immunogenicities of procholeragenoid and the B subunit of cholera toxin in Thai volunteers.
    Migasena S; Pitisuttitham P; Suntharasamai P; Prayurahong B; Supanaranond W; Desakorn V; Black RE
    Infect Immun; 1989 Jul; 57(7):1942-5. PubMed ID: 2731977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity.
    Levine MM; Nalin DR; Craig JP; Hoover D; Bergquist EJ; Waterman D; Holley HP; Hornick RB; Pierce NP; Libonati JP
    Trans R Soc Trop Med Hyg; 1979; 73(1):3-9. PubMed ID: 442179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A toxoid prepared from cholera toxin by iodination.
    Heneine IF; Lahmann WM; Rocha OA
    Braz J Med Biol Res; 1992; 25(9):913-7. PubMed ID: 1342838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intestinal antibody responses after immunisation with cholera B subunit.
    Svennerholm AM; Sack DA; Holmgren J; Bardhan PK
    Lancet; 1982 Feb; 1(8267):305-8. PubMed ID: 6120313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Experimental research on cholera vaccines. Local immunity].
    Manakhilov RB; Genova IuG; Bogatinov VT; Kostova EF
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Oct; (10):59-62. PubMed ID: 3799104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protection against colibacillosis in neonatal piglets by immunization of dams with procholeragenoid.
    Fürer E; Cryz SJ; Dorner F; Nicolet J; Wanner M; Germanier R
    Infect Immun; 1982 Mar; 35(3):887-94. PubMed ID: 7040250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of optimal mucosal antibody responses: effects of age, immunization route(s), and dosing schedule in rats.
    Pierce NF
    Infect Immun; 1984 Jan; 43(1):341-6. PubMed ID: 6606625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine.
    Svennerholm AM; Jertborn M; Gothefors L; Karim AM; Sack DA; Holmgren J
    J Infect Dis; 1984 Jun; 149(6):884-93. PubMed ID: 6736680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The adjuvant effect of pertussis endotoxin protein in modulating the immune response to cholera toxoid in mice.
    Sultzer BM; Craig JP; Castagna R
    Dev Biol Stand; 1985; 61():225-32. PubMed ID: 2872108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation of a purified antigenic cholera toxoid.
    Germanier R; Fürer E; Varallyay S; Inderbitzin TM
    Infect Immun; 1976 Jun; 13(6):1692-8. PubMed ID: 823107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cholera toxin and toxoid.
    Ungar J; Stanić M; Chariatte N; Varallyay SJ
    Prog Immunobiol Stand; 1971; 5():348-9. PubMed ID: 4660540
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunological memory after immunization with oral cholera B subunit--whole-cell vaccine in Swedish volunteers.
    Jertborn M; Svennerholm AM; Holmgren J
    Vaccine; 1994 Sep; 12(12):1078-82. PubMed ID: 7998416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera.
    Xu G; Wang S; Zhuang L; Hackett A; Gu L; Zhang L; Zhang C; Wang H; Huang Z; Lu S
    Vaccine; 2009 Jun; 27(29):3821-30. PubMed ID: 19443090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of TcpF-A2-CTB chimera and evidence of additive protective efficacy of immunizing with TcpF and CTB in the suckling mouse model of cholera.
    Price GA; Holmes RK
    PLoS One; 2012; 7(8):e42434. PubMed ID: 22879984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Priming and suppression of the intestinal immune response to cholera toxoid/toxin by parenteral toxoid in rats.
    Pierce NF; Koster FT
    J Immunol; 1980 Jan; 124(1):307-11. PubMed ID: 6965294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of cholera toxoid in an enzyme-linked immunosorbent assay for antitoxin.
    Cruce DD; Wachsmuth IK; Feeley JC
    Diagn Immunol; 1983; 1(2):87-9. PubMed ID: 6680095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of local IgA antitoxin-producing cells for intestinal protection against cholera toxin challenge.
    Lycke N; Bromander AK; Holmgren J
    Int Arch Allergy Appl Immunol; 1989; 88(3):273-9. PubMed ID: 2785966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Local and systemic antibody responses and immunological memory in humans after immunization with cholera B subunit by different routes.
    Svennerholm AM; Gothefors L; Sack DA; Bardhan PK; Holmgren J
    Bull World Health Organ; 1984; 62(6):909-18. PubMed ID: 6335849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection against experimental cholera by antitoxin.
    Pierce NF; Kaniecki EA; Northrup RS
    J Infect Dis; 1972 Dec; 126(6):606-16. PubMed ID: 4664117
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.